Categories
Uncategorized

Kirilys Therapeutics to Present Preclinical Profile for KRLS-017, a reversible inhibitor of CDK7 for Oncology

First presentation of full preclinical profile of KRLS-017, a potentially best in class reversible small molecule inhibitor of Cyclin Dependent Kinase 7 (CDK7)

San Francisco, CA, December 11, 2023 — Kirilys Therapeutics, Inc., a multi-asset biotechnology company founded by investment firm Catalys Pacific and supported by Lightspeed Venture Partners, plans to present a detailed preclinical profile for KRLS-017 at AACR 2024 in San Diego, CA.

KRLS-017 is a potent, selective, and reversible inhibitor of Cyclin Dependent Kinase 7 (CDK7) and is being developed for the treatment of patients with advanced solid tumor malignancies. CDK7 function in control of both cell cycle and gene transcription, and overexpression of CDK7 is a poor prognostic indicator in breast, ovarian, gastric, and other tumor types.

The preclinical presentation titled “Preclinical evaluation of KRLS-017, a potent, highly selective and reversible CDK7 inhibitor with broad antitumor effect in preclinical models, in preparation for a Phase 1 clinical trial in advanced solid tumor malignancies” will include pharmacology, toxicology, and efficacy across several dosing schedules using in vivo tumor models. A Phase 1 clinical program for KRLS-017 is planned as a monotherapy dose escalation study in refractory solid tumors followed by an indication-specific cohort expansion that will include breast, ovarian and potentially other transcriptionally active tumor types to evaluate anti-tumor activity.

 

About Kirilys Therapeutics, Inc.
Kirilys Therapeutics, Inc. is a private, preclinical-stage biopharmaceutical company committed to the development of multiple precision oncology assets. Kirilys’ initial asset is KRLS-017, a novel CDK7 inhibitor with the potential to improve the treatment of multiple cancers. Kirilys is headquartered in San Francisco, CA. For more information about Kirilys, please visit www.kirilys.com.

 

About Catalys Pacific
Catalys Pacific is a life sciences venture capital firm focusing on early-stage investments. The firm’s mission is to provide healthcare solutions for patients worldwide through the creation of and investment in biotech companies. Catalys Pacific is led by a global team versed in working closely with its partners in academia, biotech, venture capital and the pharmaceutical industry worldwide with an emphasis in Japan. The firm maintains offices in Tokyo and Kanagawa (Shonan Health Innovation Park), Japan and in San Francisco, California. For more information about Catalys Pacific, please visit www.catalyspacific.com.

 

About Lightspeed Venture Partners
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400+ companies globally. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia, and Europe. For more information, please visit www.lsvp.com.

Categories
Uncategorized

Kirilys Therapeutics Announces FDA Clearance of IND Application for KRLS-017, a reversible inhibitor of CDK7 for Oncology

Phase 1 clinical study will evaluate the safety, pharmacokinetics, and preliminary efficacy of KRLS-017 in treatment refractory solid tumors

San Francisco, CA, April 28, 2023 — Kirilys Therapeutics, Inc., a multi-asset biotechnology company founded by investment firm Catalys Pacific and supported by Lightspeed Venture Partners, today announced the Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1 clinical study of KRLS-017, a potentially best in class reversible small molecule inhibitor of Cyclin Dependent Kinase 7 (CDK7).

CDK7 plays a key role in control of both cell cycle and gene transcription, and dysregulation of CDK7 has been documented as a negative prognostic indicator across a broad spectrum of tumor types. The Phase 1 clinical trial of KRLS-017 is planned as a monotherapy, open-label, safety and PK/PD study for patients with treatment refractory solid tumors. The primary objective of the Phase 1a dose escalation portion of the trial is to evaluate safety and tolerability of KRS-017. Following establishment of a recommended Phase 2 dose and schedule from Phase 1a, Kirilys plans an indication-specific cohort expansion that will include breast, ovarian and potentially other transcriptionally active tumor types to evaluate anti-tumor activity.

 

About Kirilys Therapeutics, Inc.
Kirilys Therapeutics, Inc. is a private, preclinical-stage biopharmaceutical company committed to the development of multiple precision oncology assets. Kirilys’ initial asset is KRLS-017, a novel CDK7 inhibitor with the potential to improve the treatment of multiple cancers. Kirilys is headquartered in San Francisco, CA. For more information about Kirilys, please visit www.kirilys.com.

 

About Catalys Pacific
Catalys Pacific is a life sciences venture capital firm focusing on early-stage investments. The firm’s mission is to provide healthcare solutions for patients worldwide through the creation of and investment in biotech companies. Catalys Pacific is led by a global team versed in working closely with its partners in academia, biotech, venture capital and the pharmaceutical industry worldwide with an emphasis in Japan. The firm maintains offices in Tokyo and Kanagawa (Shonan Health Innovation Park), Japan and in San Francisco, California. For more information about Catalys Pacific, please visit www.catalyspacific.com.

 

About Lightspeed Venture
Partners. Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400+ companies globally. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia, and Europe. For more information, please visit www.lsvp.com.

Categories
Uncategorized

Kirilys Therapeutics Acquires ASN-004, a 5T4-targeting Antibody Drug Conjugate being evaluated in Ph1 Oncology

Ongoing Phase 1 clinical study is evaluating the safety, pharmacokinetics, and preliminary efficacy of ASN-004 in treatment refractory solid tumors

San Francisco, CA, September 1, 2022 — Kirilys Therapeutics, Inc., a multi-asset biotechnology company founded by investment firm Catalys Pacific and supported by Lightspeed Venture Partners, completed the acquisition of ASN-004 from Asana Biosciences, Inc. Kirilys plans to present the first clinical data update on ASN-004 at ASCO 2024 in Chicago, IL.
ASN004 is a 5T4-targeted Antibody Drug Conjugate (ADC) that shows high binding affinity to the human 5T4 antigen and delivers approximately 10 cytotoxic Auristatin F Hydroxypropylamide (AF-HPA) payload drug molecules per ADC molecule. ASN-004 has been previously demonstrated to have robust antitumor effects including tumor regression in preclinical tumor models.

A monotherapy Phase 1 dose escalation study (NCT04410224) is currently ongoing and PK, PD, safety and exploratory efficacy data from an interim analysis including the first 4 dose levels (1.5 – 12 mg/m2) is planned for presentation at ASCO 2024.

 

About Kirilys Therapeutics, Inc.
Kirilys Therapeutics, Inc. is a private, preclinical-stage biopharmaceutical company committed to the development of multiple precision oncology assets. Kirilys’ initial asset is KRLS-017, a novel CDK7 inhibitor with the potential to improve the treatment of multiple cancers. Kirilys is headquartered in San Francisco, CA. For more information about Kirilys, please visit www.kirilys.com.

 

About Catalys Pacific
Catalys Pacific is a life sciences venture capital firm focusing on early-stage investments. The firm’s mission is to provide healthcare solutions for patients worldwide through the creation of and investment in biotech companies. Catalys Pacific is led by a global team versed in working closely with its partners in academia, biotech, venture capital and the pharmaceutical industry worldwide with an emphasis in Japan. The firm maintains offices in Tokyo and Kanagawa (Shonan Health Innovation Park), Japan and in San Francisco, California. For more information about Catalys Pacific, please visit www.catalyspacific.com.

 

About Lightspeed Venture Partners
Lightspeed Venture Partners is a multi-stage venture capital firm focused on accelerating disruptive innovations and trends in the Enterprise, Consumer, and Health sectors. Over the past two decades, the Lightspeed team has backed hundreds of entrepreneurs and helped build more than 400+ companies globally. Lightspeed and its affiliates currently manage $10.5B across the global Lightspeed platform, with investment professionals and advisors in Silicon Valley, Israel, India, China, Southeast Asia, and Europe. For more information, please visit www.lsvp.com.

Categories
Uncategorized

Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company